Alliance Pharma

• 

  08/12/11

  Alliance Pharma’s business model “misunderstood” by stock market, says Investec

  The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors

• 

  17/11/11

  Alliance Pharma is “a stock for the times”, says Collins Stewart

  The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy

• 

  07/09/11

  Alliance Pharma’s interim results demonstrate strong underlying sales growth

  Steady sales growth among non-Deltacortril products and the prospect of further acquisitions has led house broker Numis to set a price target of 37 pence each for Alliance’s shares

• 

  20/07/11

  Alliance Pharma: Acquisition strategy continues to pay off

  Alliance Pharma focuses on speciality drugs and treatments for a range of health issues. The firm has been highly acquisitive since it was founded in 1998 and in recent years this acquisition strategy has paid off in terms of both revenue and profit. Here, we take a close look at the business

• 

  06/07/11

  Alliance Pharma a 'buy’ after trading statement, says Numis

  Numis and FinnCap both rate Alliance Pharma's shares as a 'buy' after Alliance said first-half sales would be £1 million ahead of H1 2010. Numis has set a target price of 37 pence for the shares

• 

  20/09/10

  Alliance Pharma's Growth Strategy is Paying Dividends

  Alliance Pharma has a quite compelling business model and one that seems to have caught the attention of serial entrepreneur and investor Nigel Wray. Here boss John Dawson and his finance director Richard Wright update us on the progress the company has made in a rather busy six months.

• 

  08/09/10

  Alliance Pharma should be even stronger in H2, according to Numis analyst Jonathan Kwok

  The analyst sees higher sales in the second half, and highlighted that the highly cash generative, niche drug company upped its interim dividend by 143%.

• 

  27/05/10

  Alliance Pharma trading ahead of expectations

  The Cambridge Laboratories acquisition has been successfully integrated ahead of schedule, and the group looks forward to the rest of 2010 with confidence.

• 

  24/03/10

  Alliance Pharma reports landmark full-year results with strong growth

  Sales rose 44 percent from a year earlier, driven by its rheumatology product Deltacortril, and the group is confident of further strong results in 2010.

• 

  08/02/10

  Alliance Pharma gains 18 new prescription products in acquisition

  The company is paying up to £17.8m for privately owned Cambridge Laboratories and expects the deal to be significantly earnings enhancing in the current full year.

• 

  27/08/09

  Alliance Pharma: standing the test of time

  The focus on prescription drugs means a stable revenue stream, while the fact that Alliance has a portfolio of 35 of these brands means that it is not overly dependent upon any one product for its overall revenues.

• 

  19/08/09

  Alliance Pharma to buy 2 Reckitt Benckiser drugs for £7.5 mln

  Alliance Pharma PLC (AIM: APH) said it is buying the worldwide rights to the Buccastem and Timodine brands from various subsidiaries of Reckitt Benckiser Group PLC (LSE: RB)  for £7.5 million, of which it will pay £3.7 million ia a vendor share placing.

Connect with Facebook to view or add comments for this company